14686 studies
Semaglutide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), has shown robust efficacy in glycemic control, weight reduction, and cardiovascular protection, but concerns remain regarding rare adverse events such as acute pancreatit…
AIMS: To evaluate real-world clinical use of semaglutide in obese patients, focusing on titration, tolerability and short-term efficacy. MATERIALS AND METHODS: This retrospective study included obese patients treated with the weekly injectable semagl…
Incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs), dipeptidyl peptidase-4 inhibitors (DPP-4is), and the dual GIP/GLP-1 RA tirzepatide, are widely prescribed for type 2 diabetes mellitus (T2DM). Their musculoske…
The first therapeutically useful amylin receptor (AMYR) agonist, pramlintide was based upon the structure of non-aggregating rat amylin and found limited application as an adjunct to insulin therapy. It acts centrally to induce satiety, promote weigh…
We report a rare drugs adverse effect of a GLP1-RA, presenting as severe gastric stasis, eosinophilic duodenitis, and high bowel obstruction. The patient, treated with oral semaglutide for type 2 diabetes and obesity, developed progressive upper gast…
Heart failure with preserved ejection fraction (HFpEF) affects 32 million people worldwide and is responsible for tens of billions of dollars in healthcare expenditure annually, with costs primarily driven by hospitalizations. HFpEF is notoriously di…
In the fall of 2024, a U.S. Senate Hearing on the high price of Novo Nordisk's prescription drugs Ozempic and Wegovy underlined some of the deepest challenges in the U.S. health care system. This article utilizes critical approaches to both political…
OBJECTIVE: This study aimed to evaluate the trends in antiobesity medication (AOM) and metabolic and bariatric surgery (MBS) use relative to the 2013 American Medical Association (AMA) declaration of obesity as a chronic disease and semaglutide appro…
AIM: This study assessed the cost-effectiveness of oral semaglutide versus subcutaneous dulaglutide for type 2 diabetes mellitus (T2DM) from the perspective of the Taiwanese healthcare payer, considering the self-paid status of oral semaglutide and t…
INTRODUCTION: Regulatory reviews in 2023-2024 reignited concern about possible suicidality with Glucagon-like peptide-1 (GLP-1) receptor agonists used for weight management. While clinical trials and real-world studies have not confirmed an increased…
BACKGROUND: To comprehensively evaluate the relative efficacy and safety of lifestyle interventions, pharmacological therapies (orlistat, liraglutide, and semaglutide), and bariatric surgeries [Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG)…
A 49-year-old woman developed new-onset type 1 diabetes after initiating Wegovy (semaglutide) via an online clinic, without prior screening. She experienced rapid weight loss and hyperglycemia symptoms. Blood tests indicated high GAD65 and low C-pept…
OBJECTIVE: Semaglutide shows potential in cardiovascular protection, yet its specific role and mechanism in H/R injury are unclear. Given the role of autophagy in cardiomyocyte protection and the unclear mechanism of semaglutide in H/R - induced inju…
BACKGROUND: User experience has a significant impact on pharmaceutical drug effectiveness. Social media platforms like X (formerly Twitter) have become prominent spaces where individuals share their medication-related experiences, especially with wid…
The obesity epidemic is a major health burden that enhances susceptibility to a broad spectrum of metabolic-associated comorbidities, ranging from fatty liver disease and endocrine dysfunction to traditional risks like type 2 diabetes mellitus and ca…
AIMS/HYPOTHESIS: Initial dose-escalation has been shown to mitigate gastrointestinal adverse events in people treated with incretin-based medications. We aimed to analyse dose-response relationships for the proportion of study participants reporting…